Physician profile
Nathan Luke
NPI 1508494949
$7,440.26
in general payments reported to CMS, 2019-2025
24 companies · $5,996 in 2025
The $5,996 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $28.36 · 2024: $1,416 · 2025: $5,996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,662 · Consulting Fee: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,661.90 |
| Consulting Fee | $1,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,277.46 | 2024-2025 | Biktarvy |
| Viiv Healthcare Company | $1,306.33 | 2024-2025 | Dovato, Apretude, Cabenuva |
| Genzyme Corporation | $583.36 | 2024-2025 | |
| Abbvie INC. | $378.51 | 2025 | |
| Novo Nordisk INC | $362.31 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Merck Sharp & Dohme LLC | $301.65 | 2024-2025 | Pifeltro, Delstrigo, Capvaxive |
| Leo Pharma INC. | $299.56 | 2025 | Spevigo, Anzupgo |
| Lilly USA, LLC | $294.27 | 2024-2025 | Mounjaro, Zepbound, Taltz |
| Janssen Scientific Affairs, LLC | $288.66 | 2024-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.27 | 2024 | Spevigo |
| Theratechnologies INC. | $141.21 | 2024-2025 | Trogarzo, Egrifta |
| Ucb, INC. | $133.04 | 2025 | Bimzelx |
| Biofrontera INC. | $128.86 | 2025 | |
| Blueprint Medicines Corporation | $123.26 | 2025 | Ayvakit |
| Kyowa Kirin, INC. | $120.83 | 2024 | Poteligeo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $115.13 | 2024 | Libtayo |
| Arcutis Biotherapeutics, INC. | $111.02 | 2025 | Zoryve |
| Pfizer INC. | $86.02 | 2025 | |
| Amgen INC. | $49.05 | 2022-2024 | Otezla, Repatha |
| Lundbeck LLC | $45.47 | 2025 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.82 | 2025 | Xifaxan |
| Emd Serono, INC. | $26.37 | 2025 | |
| Azurity Pharmaceuticals, INC. | $23.76 | 2025 | Azmiro |
| Tersera Therapeutics LLC | $21.04 | 2025 | Quzyttir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Luke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.